Showing 941-950 of 4649 results for "".
The State of Dermatology Entrepreneurship 2015
https://practicaldermatology.com/topics/practice-management/the-state-of-dermatology-entrepreneurship-2015/18913/William Ju, MD, President of Advancing Innovation in Dermatology talks about entrepreneurship in dermatology. Where are new ideas, technologies, and therapies coming from, and how will they move ahead? Dr. Ju talks about the role of the pharmaceutical industry and finding resources.Heliocare in Practice
https://practicaldermatology.com/topics/practice-management/heliocare-in-practice/19220/Polypodium leucotomos extract, which is derived from a tropical fern, offers benefits to users by minimizing some of the damage to the skin caused by exposure to visible light—UVA and UVB radiation—as well as invisible infrared light. Vivian Bucay, MD, discusses its activity and its role as a dispenASDS Survey: 8 Million Procedures in 2012
https://practicaldermatology.com/topics/practice-management/asds-survey-8-million-procedures-in-2012/19259/"More and more people are seeking care from dermatologic surgeons." ASDS President Timothy Flynn, MD addresses new findings about the public's dependence on dermatologic surgeons. Derm surgeons' expertise and training in cosmetic and medical care are discussed.The Neuroimmune Mechanisms Driving Prurigo Nodularis
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37136/Practical Dermatology Editorial Board member Todd Schlesinger, MD, a board-certified dermatologist and Mohs surgeon with Epiphany Dermatology in Charleston, South Carolina, discusses the neuroimmune mechanisms that drive prurigo nodularis and how they differ from those in chronic pruritus and atopicHow Incyte Is Following the Science to Address Unmet Needs in Immune-Mediated Skin Conditions
https://practicaldermatology.com/topics/infections-infectious-disease/how-incyte-is-following-the-science-to-address-unmet-needs-in-immune-mediated-skin-conditions/19945/Ahmad Naim, MD, Vice President of US Medical Affairs at Incyte, shares how the company’s discovery expertise in immunology is fueling research aimed at delivering innovative medicines that address the unmet needs of people living with immune-mediated dermatologic conditions, including atopic dermatiDermwire TV Extra: The Global Access to Skin Health Observatory
https://practicaldermatology.com/series/dermwire-tv/global-access-skin-health-observatory/29873/Esther Freeman, MD, PhD, Director of Global Health Dermatology at Massachusetts General Hospital and Harvard Medical School, and Vice Chair of the International Foundation of Dermatology with the International League of Dermatological Societies (ILDS), talks with Practical Dermatology about her workSkin of Color Session: Dr. Harris
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/skin-of-color-session-dr-harris/32683/John E. Harris, MD, PhD, summarizes his vitiligo talk from the "Skin of Color Session" at Maui Derm 2025, during which he covered new therapeutic options for vitiligo as well as promising drugs in the pipeline and why they could be so impactful.Therapeutic Approaches in Pediatric Atopic Dermatitis
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/derm-hub/37158/Robert Sidbury, MD, MPH, Chief of Dermatology at Seattle Children’s Hospital and Professor in the University of Washington Department of Pediatrics, explains how to adjust a therapeutic approach to pediatric atopic dermatitis, particularly when considering long-term use of topical steroids or calcinAdvances in Understanding the Skin’s Microbiome
https://practicaldermatology.com/series/dermatology-dispatches/advances-in-understanding-the-skins-microbiome/19772/A growing body of evidence suggests that cutaneous dysbiosis plays a role in atopic dermatitis, psoriasis, acne, and rosacea, explains Adam Friedman, MD. Efforts to encourage diversity in the skin’s microbiome with pre- and probiotics may change the way dermatologists treat these diseases in the futFDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://practicaldermatology.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis Bioteherapu